SCHEMBL19405147

SCHEMBL19405147

COc1cc2c(N3CCN(C)CC3)nc(N(C)C)nc2cc1OC1CCN(C)C1

nearest known ligand 0.83

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 15/20 0.83
TLR9 Q9NR96 14/20 0.83
EHMT2 Q96KQ7 1/20 0.56
EHMT1 Q9H9B1 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
NSD2 O96028 1/20 0.52
ACHE P22303 1/20 0.51
BACE1 P56817 1/20 0.51
KIT P10721 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19405144 0.96 TLR7 (0.90) TLR7TLR9EHMT2EHMT1SMN1; SMN2
SCHEMBL19385168 0.91 TLR7 (1.00) TLR7TLR9EHMT2EHMT1SMN1; SMN2
SCHEMBL19405220 0.91 TLR7 (0.75) TLR7TLR9EHMT2EHMT1
SCHEMBL29936942 0.91 TLR7 (0.75) TLR7TLR9EHMT2EHMT1
SCHEMBL19405146 0.88 TLR7 (0.83) TLR7TLR9EHMT2EHMT1SMN1; SMN2
SCHEMBL19405218 0.88 TLR7 (0.82) TLR7TLR9EHMT2EHMT1SMN1; SMN2
SCHEMBL29936965 0.88 TLR7 (0.82) TLR7TLR9EHMT2EHMT1SMN1; SMN2
SCHEMBL19385356 0.80 TLR7 (1.00) TLR7TLR9EHMT2EHMT1
SCHEMBL19385104 0.79 TLR9 (0.69) TLR7TLR9EHMT2EHMT1SMN1; SMN2
SCHEMBL19406433 0.78 TLR7 (0.81) TLR7TLR9SMN1; SMN2NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3433249-B1 BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST COUNCIL SCIENT IND RES (IN) 2022-11-09 EP claimed
EP-3433249-B1 BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST COUNCIL SCIENT IND RES (IN) 2022-11-09 EP disclosed
US-10662177-B2 Blocking toll-like receptor 9 signaling with small molecule antagonist COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-05-26 US disclosed
US-20190092758-A1 BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2019-03-28 US disclosed
WO-2017163264-A1 BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190092758-A1 BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST TLR9, TLR1, TLR3 TLR7 5/4885TLR9 1/4885EHMT2 1786/4885
US-10662177-B2 Blocking toll-like receptor 9 signaling with small molecule antagonist TLR9, TLR1, TLR3 TLR7 4/4885TLR9 1/4885EHMT2 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.